Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA

Author(s):  Cabaleiro Joe

Issue:  Sep/Oct 2021 - Volume 25, Number 5
View All Articles in Issue

Abstract:  In the U.S., determining whether it is legal to compound with a particular substance for human patients is governed by a patchwork of laws, regulations, and U.S. Food and Drug Administration guidance. Furthermore, there is no single, unified source where a compounder can determine whether a particular substance is legal to compound with. This article provides 503a compounders a step by- step tool to evaluate the legality of compounding with a particular substance for human patients. It does so in a systematic way that considers the patchwork of law, regulations, and U.S. Food and Drug Administration guidance documents that must be considered.

Related Keywords: Joe Cabaleiro, RPh, FACA, BCSCP, Difficult to Compound list, U.S. Food, Drug and Cosmetic Act, FDCA, drug safety, Drug Products Withdrawn or Removed from the Market for Reasons of Safety or Effectiveness list, negative list, Code of Federal Regulations, CFR, biologics, biological agents, protein, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food Drug and Cosmetic Act, Drug Quality and Security Act, DQSA, Bulk Drug Substances That Can be Used to Compound Drug Products in Accordance with Section 503A of the Federal Food Drug and Cosmetic Act, Bulks list, tetrahydrobioptermin deficiency, BH4, oxitriptan, domperidone, diethylstilbestrol, USP-NF Monograph, flowchart, investigational drugs

Related Categories: LEGAL, SUPPORT, UNITED STATES PHARMACOPEIA CONVENTIONS

Printer-Friendly Version




Download in electronic PDF format for $45

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe Sep/Oct 2021 358-362 Buy
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Nov/Dec 2016 457-458 Buy
The "Lists": What Do They Mean? Voliva John Nov/Dec 2016 477-479 Buy
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr Jul/Aug 2016 351 View Sample
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr Nov/Dec 2015 487-488 Buy
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List") Allen Loyd V Jr, Ashworth Lisa D Jan/Feb 2005 44-46 Buy
The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists Parks Kenneth Chase, Bernard Brian, Cogdill Christopher Blake Sep/Oct 2015 377-380 Buy
Basics of Compounding: The "Negative" List Allen Loyd V Jul/Aug 2015 311-313 Buy
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E Sep/Oct 2014 379-380 Buy
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr Sep/Oct 2017 356 Buy